A Brief History of Polio Vaccines
![]() |
Polio Vaccines Market |
The World Health Assembly decided in
1988 that paralytic poliomyelitis would be eradicated from the planet by the
year 2000. The global eradication campaign is nearing the end, with valiant
efforts being made to sustain polio vaccination programmes, create surveillance
systems, and eradicate the last surviving poliovirus reservoirs. Immunizing the
remaining few hard-to-reach people in distant or war-torn places, as the
smallpox eradication effort demonstrated in the 1970s, is a daunting task.
However, everyone from politicians to vaccine producers to field health workers
has rallied behind the objective of global eradication.
According to Coherent Market Insights the Polio
Vaccines Market Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026.
The prospect of a world free of polio
inspires us to hope beyond the year 2000, but there are also reasons to reflect
on the history of polio vaccine research. The first is a resurgence of interest
in the theory that HIV, the virus that causes AIDS, arose from a monkey virus
that contaminated early batches of polio vaccine used in late 1950s trials in
the Congo. As a result, it has been suggested that the few surviving batches of
the original polio vaccine supplies used in the Congo trials be tested for HIV.
A second, less well-known reason is the United States' advice. Beginning in
January of this year, children in the United States should be inoculated with
the inactivated polio vaccine produced by Jonas Salk instead of the oral polio
vaccine (OPV) developed by Albert Sabin, according to the Advisory Committee
for Immunization Practices. This shift in policy is a result of the disease's
epidemiology, but it also has repercussions for vaccine production economics.
It is clear how economics and market forces shape vaccine policy when comparing
how the United States (where private companies developed and manufactured polio
vaccines) and the Netherlands (where government-funded laboratories designed,
developed, tested, and manufactured the entire country's supply of polio
vaccine) implemented their polio vaccine programmes.
The fierce rivalry between the
original polio vaccine researchers, Salk and Sabin, was a contributing factor
in the United States and the Netherlands pursuing separate polio vaccination
campaigns. The results of the world's largest clinical trial (at the time) were
released in April 1955. More than 400,000 children in the United States had
received Salk's IPV vaccine, and when the results of effective protection
against this terrible disease were announced, Americans sighed a collective
sigh of relief. The Salk vaccine was shown to be 90% effective against Types II
and III poliovirus and 60 to 70% effective against Type I poliovirus. Salk's
IPV was approved for usage within two hours. Industrial production facilities
were already completed and ready to run thanks to guarantees from the National
Foundation for Infantile Paralysis (now the March of Dimes). By July 1955, the
goal was to have five million youngsters in the United States vaccinated.
Comments
Post a Comment